Expertise

Katya Svoboda

Senior Principal, EVERSANA Management Consulting

EVERSANA MANAGEMENT CONSULTING

Katya Svoboda

Katya comes to EVERSANA Management Consulting from ICON, where she was Senior Principal/Interim Divisional Principal, Global Pricing and Market Access. In this role, Katya worked across teams on client engagements, internal initiatives, business development, and thought leadership, with responsibility for operations, finance, and people management.

Prior to ICON, Katya was a Senior Principal at ApotheCom, where she managed and executed consulting projects and communications initiatives while building the market access practice. Before ApotheCom, Katya was a Director at Navigant, where her projects included market access and commercialization consulting. Katya also co-founded Percipient LLC, a management consulting organization focused on pricing and market access strategy consulting, where she managed much of the company’s business and operational and HR activities.

Katya has a long history in consulting, including stints as Senior Practice Executive, Pricing and Market Access, at Campbell Alliance, Senior Director, Vice President & Managing Director, at inVentiv Advance Insights, Director at Strategyx, Consultant at Skila Consulting, Senior Consultant, Manager, at Arthur Andersen, and Senior Consultant at Deloitte & Touche.

Katya holds an MBA from Yale School of Management and a master’s degree in public health from Yale School of Medicine, Department of Epidemiology and Public Health. She earned her bachelor’s degree in economics and psychology from Boston University.

Expertise:

Commercialization, Compliance, Consulting (Strategy Management & Regulatory), Market Access, Pharmacovigilance, Pricing, Reimbursement & Market Access

Articles by Katya Svoboda

COVID-19 Vaccine Safety Briefing Report

As the world awaits the fast-approaching rollout of an approved COVID-19 vaccine, developing the planning to order, distribute and track COVID-19 vaccines in the United States and globally presents an unprecedented challenge. The Food and Drug Administration (FDA) released a detailed analysis that concluded that the Pfizer and BioNTech COVID-19 vaccine is effective and safe, […]

What Happens After a COVID-19 Vaccine Trial Succeeds? 4 Pharmacovigilance Challenges to Address During Commercialization

As we near the end of 2020, we might also be near an end to the widespread illness caused by the COVID-19 pandemic. With two vaccine trials currently leading the way and more than 50 others in development, global vaccine distribution might be right around the corner. As pharma companies race to find a COVID-19 […]

Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard

The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma product.

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.